Mary Hayden, NP
Women's Health · Richmond, INNPI 1871868398
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,843 of the $3,032 with a category attached, or 60.8%. 16 manufacturers reported payments, led by Axonics, Inc. at 51.5% of the total. Reporting peaked in 2024 at $1,749 and has fallen 67.3% since, to $573 in 2025. Among women's health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $28.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- C. R. Bard, Inc. & Subsidiaries$332
- Sumitomo Pharma America, Inc.$288
- Astellas Pharma US Inc$186
- Urovant Sciences Inc$165
- Tolmar, Inc.$96
- plus $405 from 10 others
What the payments were for
- Travel & lodging$1,08936%
- Food & beverage$1,84361%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 16 | $1,561 |
| C. R. Bard, Inc. & Subsidiaries | 18 | $332 |
| Sumitomo Pharma America, Inc. | 23 | $288 |
| Astellas Pharma US Inc | 7 | $186 |
| Urovant Sciences Inc | 20 | $165 |
| Tolmar, Inc. | 5 | $96 |
| Medtronic | 4 | $87 |
| BD | 4 | $79 |
| 180 Medical, Inc. | 2 | $60 |
| Coloplast | 2 | $45 |
| Hollister Incorporated | 1 | $28 |
| Pfizer | 1 | $26 |
| Urogen Pharma, Inc. | 1 | $25 |
| Calyxo, Inc. | 1 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Laborie Medical Technologies Corp. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,032 in reported general payments places this provider in the 90th percentile of 142 women's health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 252 | $186,883 |
| MyrbetriqMirabegron | 120 | $83,276 |
| PremarinEstrogens, Conjugated | 27 | $11,883 |
| Estradiol | 168 | $10,802 |
| Mirabegron ErMirabegron | 17 | $9,180 |
| EstringEstradiol | 13 | $7,218 |
| Darifenacin ErDarifenacin Hydrobromide | 34 | $4,295 |
| Trospium Chloride ErTrospium Chloride | 24 | $2,702 |
| Solifenacin Succinate | 47 | $2,047 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 25 | $2,030 |
| Clobetasol Propionate | 73 | $1,988 |
| Fosfomycin Tromethamine | 20 | $1,901 |
| Trospium Chloride | 41 | $1,547 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $1,208 |
| NitrofurantoinNitrofurantoin Macrocrystal | 43 | $1,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $288 | $186,883252 claims |
| Astellas Pharma US IncMyrbetriq | $186 | $83,276120 claims |
| PfizerPremarin, Estring | $26 | $19,10040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 142 women's health providers in Indiana.
Other women's health in Richmond
- Melinda HegyiRichmond$506
- Cara RaunickIndianapolis$73K
- Debra TaylorGreenwood$33K
- Elizabeth FourmanNotre Dame$15K
- Amanda NakashianDyer$8K
- Courtney CortezIndianapolis$5K
- Natasha StruewingGreensburg$5K
- Rebecca PapamihalakisMunster$4K
- Kesha KellyIndianapolis$4K
- Amanda PhelpsEvansville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.